I agree that this site is using cookies. You can find further informations here.
X
Sahm, Daniel F
533  results:
Articles (Online) X
Search for persons X
?
1

Global trends in carbapenem- and difficult-to-treat-resista..:

Wise, Mark G. ; Karlowsky, James A. ; Mohamed, Naglaa...
Journal of Global Antimicrobial Resistance.  37 (2024)  - p. 168-175 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Activity of ceftolozane/tazobactam and imipenem/relebactam ..:

Karlowsky, James A. ; Lob, Sibylle H. ; Hawser, Stephen P....
European Journal of Clinical Microbiology & Infectious Diseases.  43 (2024)  7 - p. 1343-1348 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Activity of ceftolozane/tazobactam and imipenem/relebactam ..:

Karlowsky, James A ; Lob, Sibylle H ; Siddiqui, Fakhar...
JAC-Antimicrobial Resistance.  6 (2024)  3 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
4

Susceptibility of gram-negative isolates collected in Taiwa..:

Wise, Mark G. ; Karlowsky, James A. ; Chen, Wei-Ting...
Journal of the Formosan Medical Association.  123 (2024)  3 - p. 400-407 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Epidemiology and in vitro activity of ceftazidime-avibactam..:

Wise, Mark G. ; Karlowsky, James A. ; Lemos-Luengas, Elkin V...
The Brazilian Journal of Infectious Diseases.  27 (2023)  3 - p. 102759 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Activity of ceftolozane/tazobactam, imipenem/relebactam and..:

Karlowsky, James A ; Lob, Sibylle H ; Bauer, Karri A...
JAC-Antimicrobial Resistance.  6 (2023)  1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
7

Incidence of ESBLs and carbapenemases among Enterobacterale..:

Gales, Ana C ; Stone, Gregory ; Sahm, Daniel F..
Journal of Antimicrobial Chemotherapy.  78 (2023)  7 - p. 1606-1615 , 2023
Link: https://doi.org/10.1093/..
 
?
8

2119. In Vitro Activity of Aztreonam-Avibactam Against Ente..:

Estabrook, Mark ; Arhin, Francis ; Sahm, Daniel F
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
9

2153. Addition of Relebactam Increases Susceptibility to Im..:

Lob, Sibylle ; Wise, Mark G ; Chen, Wei-Ting...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
10

In vitro activity of imipenem/relebactam against non-Morgan..:

Karlowsky, James A. ; Lob, Sibylle H. ; Chen, Wei-Ting...
International Journal of Antimicrobial Agents.  62 (2023)  3 - p. 106900 , 2023
Link: https://doi.org/10.1016/..
 
?
11

2127. In vitro Activities of Ceftaroline and Comparator Age..:

Hackel, Meredith ; Stone, Gregory ; Sahm, Daniel F
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
12

Activity of ceftolozane/tazobactam and imipenem/relebactam ..:

Karlowsky, James A ; Lob, Sibylle H ; Hawser, Stephen P...
JAC-Antimicrobial Resistance.  5 (2023)  4 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
13

In VitroActivity of Ceftibuten-Avibactam against β-Lactamas..:

Karlowsky, James A. ; Hackel, Meredith A. ; Stone, Gregory G..
Antimicrobial Agents and Chemotherapy.  67 (2023)  1 - p. , 2023
Link: https://doi.org/10.1128/..
 
?
14

2150. In Vitro Activity of Cefepime-Taniborbactam and Compa..:

Wise, Mark G ; Hackel, Meredith ; Sahm, Daniel F
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
15

2155. Low prevalence of OXA-48-like carbapenemases and susc..:

Lob, Sibylle ; Wise, Mark G ; Siddiqui, Fakhar...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
1-15